NCT00515827 - Effect of Addition of Raltegravir (MK-0518) to PI- or NNRTI-Based ART Regimens in HIV Infected Subjects With Undetectable Viral Load | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

September 30, 2008

Study Completion Date

November 30, 2008

Conditions

HIV Infections

Interventions

DRUG

Raltegravir (MK-0518)

400 mg tablet taken orally twice daily

DRUG

Placebo

400 mg placebo tablet taken orally twice daily

Trial Locations (20)

10011

Cornell CRS, New York

10016

NY Univ. HIV/AIDS CRS, New York

10037

Harlem ACTG CRS, New York

14642

Univ. of Rochester ACTG CRS, Rochester

19104

Hosp. of the Univ. of Pennsylvania CRS, Philadelphia

27514

Unc Aids Crs, Chapel Hill

27710

Duke Univ. Med. Ctr. Adult CRS, Durham

44109

MetroHealth CRS, Cleveland

60611

Northwestern University CRS, Chicago

63110

Washington U CRS, St Louis

80045

University of Colorado Hospital CRS, Aurora

90502

Harbor-UCLA Med. Ctr. CRS, Torrance

94110

Ucsf Aids Crs, San Francisco

98104

University of Washington AIDS CRS, Seattle

35294-2050

Alabama Therapeutics CRS, Birmingham

94304-5350

Stanford CRS, Palo Alto

02114

Massachusetts General Hospital ACTG CRS, Boston

02215

Beth Israel Deaconess Med. Ctr., ACTG CRS, Boston

10032-3732

Columbia P&S CRS, New York

15213-2582

Pitt CRS, Pittsburgh

All Listed Sponsors

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH